MSFT 446.34 -0.4528% AAPL 214.29 -1.0984% NVDA 135.58 3.512% GOOGL 175.09 -1.213% GOOG 176.45 -1.3033% AMZN 182.81 -0.6791% META 499.49 -1.4093% AVGO 1802.52 -1.4408% TSLA 184.86 -1.3764% TSM 179.69 1.3823% LLY 891.46 0.7288% V 273.62 0.9035% JPM 197.0 1.036% UNH 481.05 -1.672% NVO 140.8 0.3063% WMT 67.6 0.267% LVMUY 152.46 -1.7021% XOM 109.38 0.9413% LVMHF 762.0 -1.8041% MA 450.11 0.4463%

Emergent Biosolutions Inc

Healthcare US EBS


Last update at 2024-06-18T20:10:00Z

Day Range


52 Week Range



Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -221.70000M 314.40M 407.20M 77.40M 81.50M
Minority interest - - - - -
Net income -223.80000M 230.90M 305.10M 54.50M 62.70M
Selling general administrative 340.30M 347.50M 303.30M 273.50M 202.50M
Selling and marketing expenses - - - - -
Gross profit 427.20M 1035.20M 1031.40M 672.50M 460.10M
Reconciled depreciation 143.30M 123.80M 114.50M 110.70M 62.20M
Ebit -166.00000M 352.60M 433.80M 114.10M 91.40M
Ebitda -34.40000M 514.40M 553.00M 226.50M 116.40M
Depreciation and amortization 131.60M 161.80M 119.20M 112.40M 25.00M
Non operating income net other -11.70000M -3.70000M 4.70M 1.70M 1.60M
Operating income -166.00000M 352.60M 433.80M 114.10M 89.80M
Other operating expenses 1286.90M 1398.40M 1121.60M 991.90M 692.60M
Interest expense 37.30M 34.50M 31.30M 38.40M 9.90M
Tax provision 2.10M 83.50M 102.10M 22.90M 18.80M
Interest income 37.30M 34.50M 31.30M 38.40M 9.90M
Net interest income -37.30000M -34.50000M -31.30000M -38.40000M -9.90000M
Extraordinary items - - - 0.00000M 4.30M
Non recurring - - - - -
Other items - - - - -
Income tax expense 2.10M 83.50M 102.10M 22.90M 18.80M
Total revenue 1120.90M 1792.70M 1555.40M 1106.00M 782.40M
Total operating expenses 593.20M 640.90M 597.60M 558.40M 370.30M
Cost of revenue 693.70M 757.50M 524.00M 433.50M 322.30M
Total other income expense net -55.70000M -38.20000M -26.60000M -36.70000M 1.60M
Discontinued operations - - - - -
Net income from continuing ops -223.80000M 230.90M 305.10M 100.30M 62.70M
Net income applicable to common shares -223.80000M 230.90M 305.10M 54.50M 62.70M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 3166.60M 3166.60M 2959.00M 2883.20M 2329.30M
Intangible assets 728.80M 728.80M 604.60M 663.10M 741.90M
Earning assets - - - - -
Other current assets 57.90M 57.90M 70.50M 36.70M 20.60M
Total liab 1783.60M 1783.60M 1340.00M 1436.20M 1240.80M
Total stockholder equity 1383.00M 1383.00M 1619.00M 1447.00M 1088.50M
Deferred long term liab - 71.80M 94.90M 53.20M 63.90M
Other current liab 142.70M 169.10M 72.90M 83.10M 6.70M
Common stock 0.10M 0.10M 0.10M 0.10M 0.10M
Capital stock 0.10M 0.10M 0.10M 0.10M 0.10M
Retained earnings 734.00M 734.00M 957.80M 726.90M 421.80M
Other liab - 90.40M 156.80M 210.70M 199.90M
Good will 218.20M 218.20M 224.90M 266.70M 268.60M
Other assets - 191.30M 57.30M 115.00M 65.60M
Cash 642.60M 642.60M 576.10M 621.30M 167.80M
Cash and equivalents - 642.60M 576.10M 621.30M 167.80M
Total current liabilities 1229.90M 1229.90M 373.80M 384.50M 216.30M
Current deferred revenue 26.40M - 140.40M 131.50M 101.90M
Net debt 763.20M 763.20M 264.90M 253.50M 643.50M
Short term debt 957.30M 957.30M 31.60M 33.80M 12.90M
Short long term debt 413.70M 957.30M 31.60M 33.80M 12.90M
Short long term debt total 1405.80M 1405.80M 841.00M 874.80M 811.30M
Other stockholder equity 645.80M 645.80M 677.20M 745.30M 676.50M
Property plant equipment - 817.60M 800.10M 644.10M 542.30M
Total current assets 1210.70M 1210.70M 1272.10M 1195.90M 686.20M
Long term investments - - - - -
Net tangible assets - 1383.00M 1619.00M 1447.00M 1088.50M
Short term investments 8.50M - - - -
Net receivables 158.40M 158.40M 274.70M 230.90M 275.30M
Long term debt 446.50M 448.50M 809.40M 841.00M 798.40M
Inventory 351.80M 351.80M 350.80M 307.00M 222.50M
Accounts payable 103.50M 103.50M 128.90M 136.10M 94.80M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 3.10M 3.10M -16.10000M -25.30000M -9.90000M
Additional paid in capital - - - - -
Common stock total equity - 0.10M 0.10M 0.10M 0.10M
Preferred stock total equity - - - - -
Retained earnings total equity - 734.00M 957.80M 726.90M 421.80M
Treasury stock - -227.70000M -152.20000M -39.60000M -39.60000M
Accumulated amortization - - - - -
Non currrent assets other 191.30M 191.30M 57.30M 113.40M 76.90M
Deferred long term asset charges - - - - -
Non current assets total 1955.90M 1955.90M 1686.90M 1687.30M 1643.10M
Capital lease obligations - - - - -
Long term debt total - 448.50M 809.40M 841.00M 798.40M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 178.30M -381.30000M -225.00000M -151.00000M -96.90000M
Change to liabilities - -52.00000M -7.70000M 61.00M 5.60M
Total cashflows from investing activities - -381.30000M -225.00000M -151.00000M -96.90000M
Net borrowings - 564.20M -35.90000M 54.50M 13.70M
Total cash from financing activities 481.20M 481.20M -141.00000M 69.50M -35.90000M
Change to operating activities - -86.50000M -29.90000M 12.00M -38.30000M
Net income -223.80000M -223.80000M 230.90M 305.10M 54.50M
Change in cash 66.30M 66.30M -45.20000M 453.50M 55.60M
Begin period cash flow 576.30M 576.30M 621.50M 168.00M 112.40M
End period cash flow 642.60M 642.60M 576.30M 621.50M 168.00M
Total cash from operating activities -34.10000M -34.10000M 321.10M 536.00M 188.00M
Issuance of capital stock 8.40M 0.00000M 0.00000M - -
Depreciation 143.30M 143.30M 123.80M 114.50M 110.70M
Other cashflows from investing activities - -21.80000M -21.80000M -10.00000M -10.00000M
Dividends paid 5.00M - 15.90M 17.80M 0.80M
Change to inventory -51.90000M -51.90000M -44.00000M -83.20000M -16.70000M
Change to account receivables 114.70M 114.70M -48.20000M 49.00M -8.20000M
Sale purchase of stock -82.10000M -82.10000M -106.00000M -13.80000M -7.40000M
Other cashflows from financing activities 597.10M 597.10M -35.00000M 456.60M 80.40M
Change to netincome - 41.80M 118.70M 104.10M 62.20M
Capital expenditures 115.80M 115.80M 225.00M 141.00M 86.90M
Change receivables - 114.70M -48.20000M 49.00M -8.20000M
Cash flows other operating - -10.30000M -56.50000M -18.00000M -23.10000M
Exchange rate changes - - - - -
Cash and cash equivalents changes - 65.80M -44.90000M 454.50M 55.20M
Change in working capital 0.50M 0.50M -94.70000M 8.80M -39.90000M
Stock based compensation 45.10M 45.10M 42.40M 51.80M 26.70M
Other non cash items 19.80M 19.80M -28.20000M 59.00M 37.60M
Free cash flow -149.90000M -149.90000M 96.10M 395.00M 101.10M


  • Previous Close 6.01
  • Market Cap290.83M
  • Volume1223138
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA100.20M
  • Revenue TTM1185.40M
  • Revenue Per Share TTM22.93
  • Gross Profit TTM 290.10M
  • Diluted EPS TTM-10.97

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
Emergent Biosolutions Inc
0.05 0.83% 6.06 - 7.94 0.10 0.17 0.84 -1.6519
Zoetis Inc
-1.24 0.73% 169.66 40.18 30.96 10.67 17.60 11.27 26.18
Merck KGaA ADR
-0.64 1.73% 36.30 21.25 14.93 3.10 2.14 3.60 12.98
MERCK Kommanditgesellschaft auf Aktien
-6.725 3.61% 179.69 21.73 14.95 3.16 2.15 3.56 12.82
Takeda Pharmaceutical Co Ltd ADR
-0.5 3.80% 12.67 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News


Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Emergent Biosolutions Inc

400 Professional Drive, Gaithersburg, MD, United States, 20879

Key Executives

Name Title Year Born
Mr. Robert G. Kramer Sr. CEO, Pres & Exec. Director 1957
Mr. Richard S. Lindahl Exec. VP, CFO & Treasurer 1964
Mr. Adam R. Havey Exec. VP & COO 1971
Mr. Atul Saran Exec. VP & Chief Strategy and Devel. Officer 1973
Mr. Robert G. Burrows VP of Investor Relations NA
Ms. Jennifer L. Fox Exec. VP of External Affairs, Gen. Counsel & Corp. Sec. NA
Ms. Coleen Glessner Exec. VP of Global Quality and Ethics & Compliance NA
Ms. Lynn Kieffer VP of Corp. Communications NA
Ms. Katherine Strei Exec. VP of HR & Chief HR Officer 1962
Mr. Richard S. Lindahl M.B.A. Executive VP, CFO & Treasurer 1964

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).